Overview

A Comparison of Once a Day Dose Compared to 2 Doses/Day

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.
Phase:
Phase 3
Details
Lead Sponsor:
Warner Chilcott
Treatments:
Mesalamine